Ads
related to: treatment for hepatitis b carriers list of diseases and medications
Search results
Results From The WOW.Com Content Network
Hepatitis C Sofosbuvir: Hepatitis C [17] nucleoside analogue reverse transcriptase inhibitor: Stavudine: HIV Taribavirin (Viramidine) Hepatitis Syndromes in which Ribavirin is active [18] Telaprevir: Hepatitis C Telbivudine (Tyzeka) Hepatitis B: Tenofovir alafenamide: Hepatitis B: Tenofovir disoproxil: Hepatitis B, HIV [19] Tipranavir: HIV ...
Hepatitis B is an infectious disease caused by the ... six months are considered to be hepatitis B carriers. ... Treatment duration when medication is taken by mouth ...
hepatitis B surfage antigen: hepatitis B Lenzilumab [6] mab: human: CSF2: chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia: Lerdelimumab [17] mab: human: TGF-β2: reduction of scarring after glaucoma surgery: Leronlimab [5] mab: humanized: CCR5: breast cancer, HIV Lesofavumab [28] mab: human: Hemagglutinin (influenza ...
Acute hepatitis B; Acute hepatitis C; Acute hepatitis D – this is a superinfection with the delta-agent in a patient already infected with hepatitis B; Acute hepatitis E; Chronic viral hepatitis; Other viral hepatitis viruses may exist but their relation to the disease is not firmly established like the previous ones (hepatitis F, GB virus C ...
Lamivudine (Epivir) is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. [4] [6] Lamivudine (Epivir HBV) is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation.
Hepatitis D is a defective virus that requires hepatitis B to replicate and is only found with hepatitis B co-infection. [17] In adults, hepatitis B infection is most commonly self-limiting, with less than 5% progressing to chronic state, and 20 to 30% of those chronically infected developing cirrhosis or liver cancer. [31]
Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (European Union) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.
The DAA drugs against hepatitis C are taken orally, as tablets, for 8 to 12 weeks. [56] The treatment depends on the type or types of hepatitis C virus that are causing the infection. [57] Both during and at the end of treatment, blood tests are used to monitor the effectiveness of the treatment and subsequent cure. [56]
Ad
related to: treatment for hepatitis b carriers list of diseases and medications